Inclusion Criteria:

- Histologically confirmed ovarian epithelial, fallopian tube or primary peritoneal
cavity cancer

- Recurrent or refractory

- Prior treatment with ≥ 1 platinum-based chemotherapeutic regimen for management of
primary disease (containing carboplatin, cisplatin, or another organoplatinum
compound) required

- Initial treatment may have included any of the following:

- High-dose therapy

- Intraperitoneal therapy

- Consolidation therapy

- Noncytotoxic agents

- Extended therapy administered after surgical or nonsurgical assessment

- Patients must meet ≥ 1 of the following criteria:

- Treatment-free interval after platinum therapy of < 12 months for patients
who received only 1 platinum-based regimen

- Progressed during platinum-based therapy

- Refractory disease after a platinum-based regimen

- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
conventional techniques OR ≥ 10 mm by spiral CT scan

- Must have ≥ 1 target lesion

- Tumors within a previously irradiated field will be designated as
"non-target" lesions unless progression is documented or a biopsy is
obtained ≥ 90 days after completion of radiotherapy

- Not eligible for a higher priority GOG protocol, if one exists

- GOG performance status (PS) 0-2 for patients who have receive one prior regimen OR
GOG PS 0-1 for patients who have received 2-3 prior regimens

- Absolute neutrophil count ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Creatinine ≤ 1.5 times upper limit normal (ULN)

- Bilirubin ≤ 1.5 times ULN

- AST ≤ 2.5 times ULN

- Alkaline phosphatase ≤ 2.5 times ULN

- No neuropathy (sensory and motor) > grade 2

- Fasting cholesterol < 350 mg/dL

- Fasting triglycerides < 400 mg/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No active infection requiring antibiotics (with the exception of uncomplicated UTI)

- No other invasive malignancies within the past 5 years, except for non-melanoma skin
cancer, breast cancer, or head and neck cancer

- See Disease Characteristics

- Recovered from prior surgery, radiotherapy, or chemotherapy

- At least 1 week since prior hormonal therapy directed at the malignant tumor

- At least 3 years since prior radiotherapy for localized cancer of the breast, head
and neck, or skin

- Patient must remain free of recurrent or metastatic disease

- At least 3 years since prior adjuvant chemotherapy for localized breast cancer

- Patient must remain free of recurrent or metastatic disease

- At least 3 weeks since other prior therapy directed at the malignant tumor, including
immunologic agents

- No prior temsirolimus

- No prior cancer treatment that would preclude study therapy

- No prior radiotherapy to > 25% of marrow-bearing areas

- No prior radiotherapy to any portion of the abdominal cavity or pelvis, except for
the treatment of ovarian cancer

- No prior non-cytotoxic therapy for management of recurrent or persistent ovarian
disease, except for therapy that was part of the primary treatment regimen

- Two additional cytotoxic regimens (defined as any agent that targets the genetic
and/or mitotic apparatus of dividing cells, resulting in dose-limiting toxicity to
the bone marrow and/or gastrointestinal mucosa) for management of recurrent or
persistent ovarian disease allowed

- Concurrent low molecular weight heparin allowed provided PT/INR ≤ 1.5

- Concurrent hormone replacement therapy allowed

- No concurrent amifostine or other protective reagents

- No concurrent prophylactic filgrastim (G-CSF)